What Ultomiris treats
Ultomiris (ravulizumab-cwvz) is a long-acting complement inhibitor used to treat rare, life-threatening blood disorders, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). By targeting part of the body’s immune system known as the complement pathway, Ultomiris helps prevent the destruction of red blood cells and protects vital organs from damage.
Benefits of Ultomiris
Patients using Ultomiris may experience:
- Fewer symptoms of hemolysis (e.g., fatigue, dark urine, anemia)
- Stabilization or improvement in kidney function (in aHUS)
- Reduced need for transfusions
- Lower risk of blood clots
- Convenient 8-week dosing interval after initial loading dose
Ultomiris provides continuous complement inhibition with fewer infusions compared to earlier therapies, improving patient comfort and treatment adherence.
Possible Side Effects of Ultomiris
Common side effects may include:
- Headache
- Diarrhea
- Nausea
- Fatigue
- Upper respiratory tract infections
Serious risks include:
- Increased risk of meningococcal infections—patients must receive a meningococcal vaccine before starting treatment
- Infusion-related reactions
- Hypersensitivity reactions
Patients are closely monitored during treatment and should report any signs of infection immediately.
How infusion works at Prime
Ultomiris is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Ultomiris, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Ultomiris Work?
Ultomiris works by binding to complement protein C5, a key component of the terminal complement cascade. In patients with PNH or aHUS, overactivation of this system leads to the destruction of red blood cells, blood clots, and organ damage. By blocking C5, Ultomiris halts this destructive process. It is administered through intravenous infusion, with a maintenance dose given every 8 weeks, making it the longest-acting C5 inhibitor currently available.
Who is Ultomiris For?
Ultomiris is approved for the treatment of:
- Adults and children with paroxysmal nocturnal hemoglobinuria (PNH)
- Adults and children with atypical hemolytic uremic syndrome (aHUS)
- Patients who are treatment-naïve or switching from another complement inhibitor (e.g., Soliris)
Ultomiris is suitable for patients requiring sustained control of complement-mediated disease activity with less frequent dosing.